Title :

Effectiveness and safety of tofacitinib in patients with chronic pouchitis multirefractory to biologics: A multicenter cohort study from the GETAID.

Author(s) :

Uzzan, Mathieu [Auteur]
Hôpital Henri Mondor
Nachury, Maria [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Amiot, Aurelien [Auteur]

Peyrin-Biroulet, Laurent [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Kirchgesner, Julien [Auteur]
CHU Saint-Antoine [AP-HP]
Bouhnik, Yoram [Auteur]
Hôpital Beaujon [AP-HP]

Journal title :

Digestive and Liver Disease

Abbreviated title :

Dig Liver Dis

Publication date :

2023-06-07

ISSN :

1878-3562

English abstract : [en]

Up to 30% of patients with ulcerative colitis (UC) will require a colectomy. Current guidelines recommend to perform an ileal pouch-anal anastomosis (IPAA) as restorative surgery following colectomy. About half of the ...
Show more >Up to 30% of patients with ulcerative colitis (UC) will require a colectomy. Current guidelines recommend to perform an ileal pouch-anal anastomosis (IPAA) as restorative surgery following colectomy. About half of the patients with IPAA will experience at least one episode of inflammation of the pouch, called acute pouchitis [ [1] ]. Among them, approximately 10% to 15% will present chronic pouchitis [ [1] ]. For chronic refractory pouchitis, anti-TNF agents including infliximab and adalimumab have been shown to be effective to induce response and remission [ [2] ]. Recent reports have suggested that vedolizumab and ustekinumab may be also considered in these patients [ [3] , [4] ]. Vedolizumab is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have had an inadequate response with or lost response to antibiotic therapy, following the completion of the randomized controlled trial, the EARNEST study [ [5] ]. Despite the increasing number of therapeutic options, including biologics, many patients will fail available biologics. This represents a very challenging condition in routine clinical practice.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-30T22:08:16Z
2024-03-11T13:43:04Z